Leading the Way in Life Science Technologies

GEN Exclusives

More »

The Lists

More »
Jul 31, 2012

Top Paid Women in Biopharma

GEN’s listing of the 25 highest-paid females in the industry.

Top Paid Women in Biopharma

These 25 women are pulling in the big bucks. [© stefa_neve - Fotolia.com]

  • #10. Robin Smith

    CEO, NeoStem

    2011 Compensation: $3,647,772

  • #9. Robin L. Washington

    SVP and CFO, Gilead Sciences

    2011 Compensation: $4,032,193

  • #8. Silvia Ayyoubi

    Head of Human Resources, Roche

    2011 Compensation: $4,035,692

  • #7. Sandra Leung

    General Counsel and Secretary, Bristol-Myers Squibb

    2011 Compensation: $5,491,673

  • #6. Laura J. Schumacher

    EVP, General Counsel and Secretary, Abbott Laboratories

    2011 Compensation: $5,567,493

  • #5. Amy W. Schulman

    EVP, General Counsel, President and GM, Nutrition, Pfizer

    2011 Compensation: $5,764,662

  • #4. Beatrice Cazala

    EVP Commercial Operations, Bristol-Myers Squibb

    2011 Compensation: $5,941,167

  • #3. Naomi Kelman

    Head of Novartis OTC Division, Novartis1

    2011 Compensation: $6,927,529

  • #2. Sherilyn S. McCoy

    Vice Chairman, Executive Committee, Johnson & Johnson

    2011 Compensation: $8,733,678

  • #1. Heather Bresch

    CEO, Mylan

    2011 Compensation: $9,640,486

  •  

    Leave a comment by clicking the “Comments” icon below. We want to hear your thoughts!



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »